Insmed (NASDAQ: INSM) reported Q2 EPS of ($1.70), $0.40 worse than the analyst estimate of ($1.30). Revenue for the quarter came in at $107.4 million versus the consensus estimate of $103.41 million.

For earnings history and earnings-related data on Insmed (INSM) click here.